3 min read

How many antibiotics are there?

The WHO classified 268 antibiotics used in humans in 2025, including 50 on its Essential Medicines List. The exact total depends on whether the count covers active substances, products, or classes.

Matic Broz

Computational chemist

The closest current global count is 268 antibiotics used in humans. That is the number assigned to the World Health Organization's Access, Watch, or Reserve groups in 2025.

It is not a count of every antibiotic brand, dose, formulation, veterinary drug, topical treatment, or experimental compound. There is no single worldwide total that covers all of those categories.

How many antibiotics are there?

The WHO classified 268 antibiotics used in humans in 2025. This is the clearest current worldwide reference count.[1]

The number depends on the unit being counted. The 268 figure covers antibiotic substances in the WHO's global stewardship system. The 2025 WHO Model List of Essential Medicines contains a narrower selection of 50 antibiotics for priority health needs.[1] Neither figure counts every branded product separately. The same active-substance-versus-product distinction explains why broader counts of medicines worldwide differ.

The WHO list has expanded as more drugs have been classified. It contained 180 antibiotics in 2019 and 257 in 2023 before reaching 268 in 2025.[2][3][1]

The number of antibiotics in the WHO AWaRe classification increased from 180 in 2019 to 268 in 2025

These releases are comparable counts of antibiotics assigned to the WHO's Access, Watch, or Reserve groups. Access antibiotics are preferred for many common infections, Watch antibiotics have higher resistance potential, and Reserve antibiotics are held back for infections with few suitable alternatives.

How many classes of antibiotics are there?

The WHO's ATC system has 10 main groups for systemic antibacterials. There is no universal class count because antibiotics can also be grouped by chemical structure, mechanism, spectrum, or use.[4][5]

Those 10 groups are tetracyclines, amphenicols, penicillins, other beta-lactams, sulfonamides and trimethoprim, macrolides/lincosamides/streptogramins, aminoglycosides, quinolones, antibacterial combinations, and other antibacterials.[5]

Popular lists often count cephalosporins, carbapenems, and monobactams as separate classes. The ATC system places them together under “other beta-lactam antibacterials.” This difference in splitting and grouping explains why credible class counts do not always match.

How many antibiotics are there for UTIs?

Current European guidelines name four first-line antibiotic options for cystitis in women: fosfomycin, pivmecillinam, nitrofurantoin, and nitroxoline. There is no fixed count for every type of UTI.[6]

The same guideline lists cephalosporins, trimethoprim, and trimethoprim-sulfamethoxazole as alternatives under specific conditions. Kidney infections, complicated UTIs, pregnancy, allergies, kidney function, and resistant bacteria require different choices.

The available list also changes. The US Food and Drug Administration approved pivmecillinam for uncomplicated UTIs in adult women in 2024 and gepotidacin for uncomplicated UTIs in female patients aged 12 years and older in 2025.[7][8] A urine culture and local resistance data can narrow the appropriate options for an individual infection.

Are new antibiotics still being developed?

New antibiotics are still being developed. In 2025, the WHO counted 90 antibacterial agents in clinical development, but only 15 met at least one of its innovation criteria and only five were active against at least one critical-priority bacterium.[9]

Of 90 antibacterial agents in clinical development in 2025, 15 met a WHO innovation criterion and five targeted at least one critical-priority bacterium

Seventeen antibacterial agents targeting priority pathogens received marketing authorization between July 2017 and February 2025. Only two represented a new chemical class.[9]

The pipeline spans drug discovery, molecular docking, laboratory studies, and clinical trials. An experimental candidate does not add to the 268-antibiotic reference count merely by entering development; AWaRe classifies antibiotics used in humans.

ProteinIQ. "How many antibiotics are there?" Published July 28, 2026. Accessed [your access date]. https://proteiniq.io/guides/how-many-antibiotics-are-there

Sources
  1. WHO definitions for reserve antibiotics Bulletin of the World Health Organization · 2025. https://cdn.who.int/media/docs/default-source/bulletin/online-first/blt.25.293893.pdf?sfvrsn=9ed3588_3
  2. WHO releases the 2019 AWaRe Classification Antibiotics World Health Organization · 2019. https://www.who.int/news/item/01-10-2019-who-releases-the-2019-aware-classification-antibiotics
  3. Proposal to classify antibiotics not currently included in the WHO AWaRe classification World Health Organization · 2025. https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/late-papers/l.4_aware-classifications.pdf?sfvrsn=28b75898_1
  4. Classes of antibiotics Global Antibiotic Research and Development Partnership · July 28, 2026. https://revive.gardp.org/resource/classes-of-antibiotics/
  5. ATC/DDD Index: J01 Antibacterials for systemic use WHO Collaborating Centre for Drug Statistics Methodology · July 28, 2026. https://atcddd.fhi.no/atc_ddd_index/?code=J01
  6. EAU Guidelines on Urological Infections European Association of Urology · 2026. https://uroweb.org/guidelines/urological-infections/chapter/the-guideline
  7. FDA approves new treatment for uncomplicated urinary tract infections U.S. Food and Drug Administration · 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections
  8. Drug Trials Snapshots: BLUJEPA U.S. Food and Drug Administration · 2025. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-blujepa
  9. WHO releases new reports on new tests and treatments in development for bacterial infections World Health Organization · 2025. https://www.who.int/news/item/02-10-2025-who-releases-new-reports-on-new-tests-and-treatments-in-development-for-bacterial-infections
Matic Broz

Founder and computational chemist, ProteinIQ

Dr. Matic Broz is the founder of ProteinIQ and a computational chemist. He completed a PhD focused on protein structure, molecular dynamics, and neural networks, and writes about structural biology and scientific software.